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Abstract
DNA fragmentation is a well-recognized hallmark of apoptosis. However, the precise DNA sequences cleaved during
apoptosis triggered by distinct mechanisms remain unclear. We used next-generation sequencing of DNA fragments
generated in Actinomycin D-treated human HL-60 leukemic cells to generate a high-throughput, global map of apoptotic
DNA breakpoints. These data highlighted that DNA breaks are non-random and show a significant association with active
genes and open chromatin regions. We noted that transcription factor binding sites were also enriched within a fraction of
the apoptotic breakpoints. Interestingly, extensive apoptotic cleavage was noted within genes that are frequently
translocated in human cancers. We speculate that the non-random fragmentation of DNA during apoptosis may contribute
to gene translocations and the development of human cancers.
Citation: Fullwood MJ, Lee J, Lin L, Li G, Huss M, et al. (2011) Next-Generation Sequencing of Apoptotic DNA Breakpoints Reveals Association with Actively
Transcribed Genes and Gene Translocations. PLoS ONE 6(11): e26054. doi:10.1371/journal.pone.0026054
Editor: Swati Palit Deb, Virginia Commonwealth University, United States of America
Received July 11, 2011; Accepted September 16, 2011; Published November 8, 2011
Copyright:  2011 Fullwood et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by Duke-NUS funds to S.S. and a Singapore Ministry of Education grant (T1) to M.J.F. M.J.F. is supported by a Lee Kwan Yew
Postdoctoral Fellowship and a L’Oreal for Women in Science Fellowship. The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Shirish.shenolikar@duke-nus.edu.sg
Introduction
Many anti-cancer drugs induce cell death in target cells via
programmed cell death or apoptosis [1]. Apoptosis, which is also
important in normal tissue development, is significantly activated
during many pathological conditions and involves nuclear conden-
sation and fragmentation of genomic DNA and its subsequent
engulfment by neighboring cells [2]. A complex network of
biochemical pathways trigger or modulate apoptosis in mammalian
cells. For example, the activation of a cascade of caspases, a family
of thiol proteases, leads to the cleavage of numerous proteins that in
turn results in alterations in cell morphology that are characteristic
of apoptosis. In addition, the Bcl-2 extended family members, such
as BAX, function as inhibitors of apoptosis and may dictate the
precise timing of cell death [3]. Yet other cellular pathways, such as
those activated by the tumor suppressor gene, p53, connect
apoptotic mechanisms with extrinsic and intrinsic signals [4,5,6]
that also control cell death [7].
The process of apoptosis has been extensively studied using a
wide array of technologies such as microarrays, whole genome
small interfering RNA (siRNA) screens and proteomics. This
provided valuable insights into genes and proteins that regulate
apoptosis [8,9,10,11]. For example, microarray analyses of cells
undergoing p53-induced apoptosis suggested that expression of the
Apaf-1 gene as well as other proapoptotic genes induced by p53
directed cells into apoptosis [9]. Use of microRNAs and siRNAs
identified genes such as CDK4 that modulates TRAIL-induced
apoptosis [11]. Other small interfering RNA screens highlighted
the importance of E2F1-PUMA and ERK-MAP3K8 signaling in
thapsigargin-induced apoptosis [8]. These studies emphasized the
remarkable diversity of signaling pathways that triggered apoptosis
in response to distinct noxious stimuli.
Fragmentation into a characteristic DNA ‘‘ladder’’ with
fragments representing multiples of approximately 180 bp was
proposed to result from intranucleosomal cleavage of genomic
DNA during apoptosis [12]. Genomic DNA fragmentation is also
frequently monitored by the terminal deoxynucleotidyl transfer-
ase-mediated nick end labeling (TUNEL) using biotinylated dUTP
[13] but the precise sequences cleaved and the DNases responsible
are still largely unknown. For example, apoptosis-inducing factor
(AIF) promotes the degradation of chromatin into high molecular
weight fragments of approximately 50 kilobases [14]. This pattern
may reflect the higher ordered organization of the genomic DNA
into complex 3-dimensional structures mediated by chromatin
interactions. Yet other factors, such as DNase II, are present in the
neighboring cells and can further degrade engulfed or phagocy-
tosed DNA in the final pattern of DNA fragments seen during
apoptosis [15].
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ase (CAD), also known as the DNase Fragmentation Factor (DFF),
as the primary DNase that cleaves genomic DNA within the dying
cells into the characteristic pattern or nucleosomal ‘‘ladder’’ seen
during apoptosis [16]. As noted above for apoptosis, CAD plays
roles outside human disease, by promoting cell differentiation
through the induction of DNA breaks [17]. Interestingly, CAD
knockout mice show an increased susceptibility to cancer [18], and
CAD mutations are also commonly seen in human cancers
[19,20]. Also, CAD is aberrantly expressed in some cancer cells. In
human hepatoma cells, alternatively spliced CAD transcripts have
been found, potentially contributing to the ability of these cells to
circumvent apoptotic signaling that leads to cell death [21]. These
data not only suggest a close link between CAD-mediated DNA
cleavage and cancer but when combined with the observed
resistance of most human cancer cells to apoptosis [22], they hint
at the aberrant activation of CAD and consequent DNA breaks in
gene translocations and other genomic perturbations in the
process of cell transformation and oncogenesis.
Previous experiments suggested that genomic DNA is degraded
in a ‘‘homogenous’’ manner during apoptosis [23]. However, these
and other studies of apoptotic DNA were limited in their
throughput, and yielded conflicting results on whether apoptotic
breakpoints were biased towards gene-poor (heterochromatin) or
gene-rich (euchromatin) regions of the chromatin. For example,
fluorescence in situ hybridization experiments showed a distinct
bias in the apoptotic breakpoints towards heterochromatin [24].
By contrast, Sanger sequencing of cloned apoptotic DNA
fragments in chicken liver suggested that apoptotic DNA cleavage
sites were non-random and significantly biased towards genes [25].
Ligation-mediated PCR of selected cleavage sites also suggested a
non-random mechanism for DNA fragmentation during apoptosis
[26].
One of the implications of selective cleavage of genomic DNA
during apoptosis is that the free or exposed DNA ends may be
more prone to conferring gene translocation if rapid DNA repair
occurred and the cell escaped apoptosis through acquiring a
growth advantage, or if incorporated into the genome of a
neighboring cell.
Rapid DNA repair upon a catastrophic genome shattering event
which would otherwise lead to apoptosis of the cells has been
suggested to occur in cancer cells, in a process called ‘‘chromo-
thripsis’’, whereby up to hundreds of genomic translocations may
occur in a single cellular event [27]. While chromothripsis has
been suggested to occur because of shattering of a condensed
chromosome during mitosis by ionizing radiation, another
mechanism for chromothripsis may be that apoptosis leads to
widespread genomic fragmentation, which may then be repaired
in the cell, and the resulting rearrangements can lead to a growth
advantage.
As an alternative mechanism, fragmented apoptotic DNA from
tumors was shown to undergo ‘‘horizontal gene transfer’’, namely
the ability to transfer into the genome of surrounding cells, most
likely through their engulfment of apoptotic or dying cells [15].
This process can be remarkably efficient [28], requires CAD [29],
and may induce tumor formation in vivo, possibly through the
induction of gene translocations [30]. The tumor suppressor gene
p53 prevents cells from replicating the transferred DNA, providing
a possible explanation for the ability of cells carrying a mutant p53
gene to acquire genetic alterations [15]. Furthermore, studies of
the MLL gene suggested that selected apoptotic DNA breakpoints
closely mapped to sites of translocations in this gene noted in
human cancers [31,32,33,34,35]. We speculate that integration of
apoptotic DNA into the genomes of normal cells through
horizontal gene transfer may lead to observed ‘‘chromothripsis’’
events.
To better understand the relationship between apoptosis, DNA
breakpoints and gene translocations, a genome-wide map of
apoptotic DNA breakpoints is required. To analyze DNA
breakpoints in a high-throughput, de novo and global manner, we
developed a novel ‘‘Apoptoseq’’ methodology (Figure 1, panel A)
described here. The application of the ‘‘Apoptoseq’’ methodology
to Actinomycin D-treated HL-60 human leukemic cells yielded the
first full genome apoptotic DNA breakpoint map (Figure S1;
Table 1; Table S1). These data established that apoptotic DNA
breakpoints were non-random, and frequently associated with
actively transcribed genes residing in open regions of the
chromatin and at sites where transcription factors are known to
bind. Comparison of the apoptotic cleavage sites with sites of
frequent translocations found in human cancers suggests a possible
link between the cellular mechanisms that contribute to apoptosis
and gene translocation.
Results and Discussion
Apoptoseq
During apoptosis, cellular DNases cut internucleosomal regions
into double-stranded DNA fragments of 180–200 bp [12], which
are seen as a ‘‘ladder’’ of DNA fragments following agarose gel
electrophoresis. For ‘‘Apoptoseq’’, we excised the most highly
cleaved 180 bp DNA band, on the basis that this represents the
most cleaved fraction of the apoptotic ladder, and is therefore a
good candidate for initial studies of the apoptotic ladder. In later
experiments, other higher migrating DNA bands were also
analyzed. As the apoptotic DNA possessed either blunt ends or
39 overhangs [36], the DNA fragments were subjected to blunt-
ending, followed by sequencing adapter ligation as described in
Methods. The ensuing DNA sequencing protocol utilized the
procedure for the ABI SOLiD [37] next-generation sequencing
library construction. The fact that apoptotic DNA breaks could be
ligated was previously established using ligation-mediated PCR to
amplify these apoptotic DNA fragments [26]. We sequenced the
equivalent of 1–2 octets of one plate of ABI SOLiD per library, for
all libraries, and 50 base tags were produced (Figure 1, panel A).
We then aligned raw sequences to the human genome to
identify the origins of the DNA fragments. Specifically, we
mapped all reads to the hg19 human genome assembly using
Batman v2.0 (Tennakoon et al, manuscript in preparation). We
sequenced the ends of the 180 bp DNA fragments, in numerous
repeat experiments. We predicted that randomly cleaved DNA
would be less likely to be sequenced in many repeat experiments
and thus, would distribute in a scattered or random manner across
the genome. In contrast, the apoptotic cleaved DNA would be
more clustered. Specifically, we used a Chromatin Immunopre-
cipitation with Sequencing (ChIP-Seq) software application,
MACS [38], to call the peaks for these reads. We adopted the
MACS software for identifying peaks in the full-genome apoptotic
maps, as the 180 bp fragments enriched at apoptotic breakpoint
cut sites were analogous to transcription factor binding sites
enriched in 180 bp DNA fragments using ChIP-Seq methodology.
Thus, an Apoptoseq peak represents a region of non-random
clustered tags from the ends of DNA cut during apoptosis and a
putative apoptotic breakpoint.
Identification of non-random apoptotic breakpoints
We analyzed two biological replicates (libraries AHH001 and
AHH002) of HL-60 cells treated with Actinomycin D for 19 hours
(Table 1). Actinomycin D, which has been used to treat cancers,
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PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e26054Figure 1. The Apoptoseq Method. A. Schematic of the Apoptoseq methodology is shown. B. Screenshot of the apoptotic DNA patterns for the
CASP3 gene Track labels: 1 – AHH001 biological replicate 1 Apoptoseq sequence density. 2 – Peaks called from AHH001. 3 - AHH002 biological
replicate 2 Apoptoseq sequence density. 4 – Peaks called from AHH002. 5 – UCSC Genes. 6 – DNase I hypersensitivity Sequencing Peaks (1 indicates a
peak is present, 0 indicates no peak is present) [53]. 7 – H3K4me3 ChIP-Seq Peaks (1 indicates a peak is present, 0 indicates no peak is present) [53]. 8
– CTCF ChIP-Seq Peaks (1 indicates a peak is present, 0 indicates no peak is present) [53]. C. Screenshot of the apoptotic DNA patterns for the MYB
gene. Track labels follow labels in Figure 1B.
doi:10.1371/journal.pone.0026054.g001
Table 1. Statistical Analyses of Apoptoseq Libraries.
Sample Total Reads Uniquely mapped Peaks
Actinomycin D-treated HL-60 cells, Biological Replicate 1 (AHH001) 38 million 15 million 7,413
Actinomycin D-treated HL-60 cells, Biological Replicate 2 (AHH002) 108 million 38 million 255,488
Composed of 2 technical replicates (AHH002A, AHH002B)
AHH002A 55 million 18 million 132,580
AHH002B 54 million 20 million 125,774
Apoptoseq libraries were generated from Actinomycin D-treated HL-60 cells and analyzed as described in Methods.
doi:10.1371/journal.pone.0026054.t001
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through the inhibition of RNA polymerase [40].
After removing duplicated reads arising from clonal PCR
amplification and performing peak-calling to identify statistically
significant sequence clusters (or peaks), we noted 7,413 peaks in
one – AHH001 - library and 255,488 peaks in the other –
AHH002 - library (Table 1; Table S1; Table S2). These data
indicated that at least a fraction of apoptotic breakpoints were
non-random as sequencing random fragments would not be
expected to yield statistically significant peaks. The peaks showed a
wide distribution in intensities. In general, there were fewer high-
intensity peaks and many more low-intensity peaks (Figure S2).
After accounting for sequencing depth, there was still a
significant difference in the numbers of peaks from the two
libraries. To investigate whether these represented technical
variability in the preparation of the libraries, we undertook two
technical replicates of one of the biological replicates (AHH002A
and AHH002B). The technical replicates were prepared from the
same sample. Therefore, the comparison of these two replicates
served as an important control to evaluate potential variations in
the library preparation. Here, we found good agreement between
these technical replicates, which were sequenced to similar
sequencing depths, with 132,580 peaks obtained for AHH002A
and 125,774 peaks for AHH002B (Table 1). Moreover, upon
closer inspection of a number of cleavage sites, we found that the
technical replicates displayed remarkably similar patterns (Figure
S3, panel A). Overlapping the peaks, we found a high degree of
similarity with 58% of AHH002A sites overlapping with those in
AHH002B (51584 of 125774) (Figure S3, panel B). The intensities
of peaks in the two technical replicates also showed a high degree
of reproducibility (r=0.837; Figure S3, panel C). Based on these
findings, we attributed the differences in peaks in the two
biological replicate libraries to be due to biological and not
technical variability.
Further examination of the biological replicates, AHH001 and
AHH002, focused on specific cleavage sites (Figure 1, panels B &
C, Figure S4, Panel A to F). We found good agreement in the
location of the peaks in the two libraries (Figure 1, panels B & C:
Figure S4, panels A to F) with certain sites showing similar trends
between both replicates. However, the signal-to-noise ratio in only
one biological replicate was large enough to clearly call an
apoptotic breakpoint peak (Figure S4, panel B). Plotting the data
as genome-wide maps revealed peaks in all chromosomes (Figure 2,
panel A), indicating that Apoptoseq methodology identified
apoptotic breakpoints in a global manner. The genome-wide
maps from the two biological replicates were also very similar. The
majority of peaks in AHH001 (4520 of a total of 7413 sites, 61%)
overlapped with those in AHH002, establishing the reproducibility
of Apoptoseq (Figure 2, panel B). Comparison of the peak
intensities of AHH001 with AHH002 indicated a correlation
(r=0.669; Figure 2, panel C), further emphasizing the reproduc-
ibility of the Apoptoseq method. Possible reasons for a lack of
overlap between the two biological replicates may include
variation in the time taken to respond to the apoptotic stimulus,
such that cells in later stages of apoptosis experienced greater
DNA fragmentation than cells at earlier stages of apoptosis.
Alternatively, sample-to-sample variation in chromosomal regions
susceptible to CAD cleavage could contribute to this outcome.
Further work will be clearly needed to evaluate the basis for the
biological variation.
We validated 15 distinct loci for apoptotic cleavage including 13
found in both AHH001 and AHH002 libraries and 2 negative
controls quantitative PCR (Figure 3, panels A & B; primers listed
in Table S3). These loci were chosen from breakpoints near
apoptotic genes (e.g. CASP3) and frequently translocated genes
(e.g. MYB), as well as regions of the genome without any known
relation to either apoptosis or translocations. The loci are
identified by their position with respect to the closest genes. We
also used quantitative PCR to analyze the 180 bp band that was
gel-excised from apoptotic ladders prepared in the lab. Apoptosis
was confirmed by western immunoblot analysis of cleaved PARP
(Figure S5, panel A). We normalized the data against uncut,
purified HL-60 genomic DNA. This took into account any
chromosomal abnormalities in HL-60 cells. To adjust for any
differences in loading, we normalized our data against one
negative or control primer (Table S3) complementary to genomic
DNA regions that were not subject to apoptotic cleavage. Again,
some variability between biological replicates was seen. While 4 of
the 13 primer pairs (CPAMD8, BCR, IFRD1, MET) showed modest
enrichments as compared with the negative control, 9 primer pairs
showed excellent enrichments against the same control. Moreover,
3 primer pairs (ZSCAN22, HECW2, CREB3L2) showed remarkably
high enrichments (Figure 3, panel A). We also ran qPCR reactions
with 7 primer pairs against 180 bp fragments from commercially
available DNA derived from Actinomycin D-treated HL-60 cells
and observed similar enrichments to that from apoptotic DNA
prepared in-house (Figure S5, panels B & C).
Next, we examined apoptotic breakpoints in larger DNA
fragments in the apoptotic ladder. Specifically, we analyzed the
360 bp DNA fragments from Actinomycin D-treated using 7
primer pairs in qPCR (Figure S6, panel A). The 360 bp fragments
showed similar general trends in terms of the genes cleaved as the
180 bp fragments (Figure S5, panel B), but showed slightly lower
fold changes. Interestingly, the BCR gene showed a higher fold
change in the 360 bp fragments. By contrast, the entire apoptotic
ladder showed very low fold changes compared with background
(Figure S6, panel B). The latter results are consistent with the
notion that large DNA fragments are generated by more limited
cleavage by apoptotic DNases and highlight the need to isolate the
180 bp (or 360 bp) fragments to identify the apoptotic break-
points. While an alternative sequencing methodology could utilize
DNA isolation via tags added to the ends of all DNA fragments,
validations of this approach would still require quantitative PCR
and necessitate isolation of the 180 bp or 360 bp fragments.
Whether apoptotic breakpoints were changed with increasing
exposure to cytotoxic drug was assessed by comparing the qPCR
results obtained for 180 bp fragments from HL-60 cells treated
with Actinomycin D at 4 hours (Figure S6, panel C) and those
treated for 19 hours (Figure S5, panel B). However, we observed
little difference in the fold inductions of amplified DNA using 7
selected primer pairs. This suggested that DNA fragmentation in
the Actinomycin D-treated HL-60 cells had already arrived at an
end stage by 4 hours.
Genes Associated with Apoptotic Breakpoints
The full genome maps of apoptotic breakpoints were compared
with UCSC genes for overlaps with putative promoters, exons,
introns, 39 sequences and even some more distal regions from
genes (up to 20 kb from the transcription start site) (Figure 4, panel
A; Table S2; Table S4). We noted that many apoptotic
breakpoints were located within introns, with some present in 59
and 39 regions of genes and in exons (Figure S4, panels A to H;
Figure 4, panel B). Interestingly, there were significantly more
apoptotic breakpoints associated with the regions distal to
promoters and in promoter regions as compared to random
regions of the genome (Figure 4, panel B; chi-square p-
value=1.06
211 for distal promoters in AHH001; chi-square p-
value,2.2
216 for promoters in AHH001; chi-square p-val-
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216 for distal promoters in AHH002; chi-square p-
value,2.2
216 for promoters in AHH002). This data suggested
that during apoptosis, intranucleosomal cleavage of genomic DNA
was significantly concentrated at the promoters of most likely
actively-transcribed genes [41].
In the AHH001 DNA fragment library, 4595 of 7413 break-
points (62%) were associated with genes. In AHH002, essentially
similar (62% or 159611 of 255488) breakpoints were associated
with genes. By contrast, only 128255 of 248999 (52%) random
sites selected in the whole genome showed an association with
genes. In performing the significance calculations, the Pearson’s
chi-square p-value of AHH001 was 2.5
2201; and the Pearson’s chi-
square p-value of AHH002 was 0 (Figure 4, panel B; Table S2;
Table S4). This association of apoptotic DNA breakpoints with
genes was also seen by comparing gene density with apoptotic
peaks, as shown for Chromosome 14 (Figure 4, panel C). As
UCSC lists both gene transcripts and genes, both UCSC gene ID
(transcript ID) and gene symbol (gene ID) are shown for each
Figure 2. Comparison of Apoptoseq Replicates. A. Genome-wide graphs of AHH001 and AHH002. B. Venn diagram of overlaps between
AHH001 and AHH002. The number in the pink circle indicates AHH002 peaks that did not overlap with AHH001 peaks. The number in the blue circle
indicates unique AHH001 peaks that did not overlap with AHH002 peaks. The top number in the purple or overlapping region indicates AHH002
peaks that overlap with AHH001 peaks and the bottom number indicates AHH001 peaks that overlapped with AHH002 peaks. C. Graph comparing
the peak intensities of overlapping regions in AHH001 and AHH002.
doi:10.1371/journal.pone.0026054.g002
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transcripts comprising of 2807 genes. By comparison, AHH002
was associated with 44179 gene transcripts from 17321 genes
(Table S4). Moreover, the GC content of apoptotic breakpoints in
AHH001 was 49% while that for AHH002 was 52%, both greater
than the average of 41% for the full genome [42]. As genic regions
of the genome are associated with higher GC content [43], the
observed high GC content of apoptotic breakpoints also suggests a
higher gene density at the apoptotic breakpoints.
Interestingly, some genes were highly cleaved during apoptosis,
while others were either rarely cleaved or not at all (Figure S4,
Table S4). One example of a highly cleaved gene was FHIT,a
tumor suppressor gene located at a very common fragile site
(FRA3B) (Figure S4). As fragile sites are often associated with gene
translocations [44,45], these data suggested that some apoptotic
DNA breakpoints might be associated with translocations.
Apoptotic breakpoints were also noted in the MLL gene in one
of the two biological replicates (Figure S4, panel D). MLL is a gene,
which was previously associated with gene translocation and
apoptotic cleavage in human leukemia cells, raising the possibility
that other translocated genes may be associated with apoptotic
cleavage [31,32,33,34,35]. Apoptotic breakpoints were also found
in the MYB gene (Figure S4, panel D), which is commonly
dysregulated in human cancers and also found to be susceptible to
translocations [46]. Other examples of translocation-prone genes
[47] are shown in Figure S4D.
To further explore the link between translocation-prone genes
and apoptotic DNA breakpoints, we examined the cancer-
associated genes and translocation-associated genes curated by
Michael Stratton, Andy Futreal, and colleagues at the Wellcome
Trust Sanger Institute [47]. Of the known cancer-associated genes,
70 of 2807 (2.5%; chi-square p-value,0.001) genes were
associated with cancers in the AHH001 fragment library, and
308 of 17321 (1.8%; chi-square p-value,0.001) genes in AHH002
were also associated with cancer. This is compared to only 378 of
the total of 29209 UCSC genes (1.3%) in the human genome. Of
translocation-prone genes, we found that 48 of 2807 (1.7%; chi-
square p-value,0.001) genes in AHH001, and 207 of 17321
(1.2%; chi-square p-value,0.001) in AHH002 were associated
with translocations, compared with only 252 of the total 29209
genes (0.9%) in the entire human genome (Table S4). While the
percentage of apoptotic genes associated with translocations
appears low, at least some genes cleaved during apoptosis may
result in translocations that are toxic or lethal to cells and thus
would not be present in the above cancer database. For example,
CASP3 was cleaved during apoptosis, and this breakpoint was
validated by quantitative PCR (Figure 1; Figure 3), but CASP3 is
not associated with any recorded translocations in human cancers.
Interestingly, in addition to CASP3, several genes encoding
caspases and other factors involved in apoptosis, such as DFFA and
DFFB, both components of the caspase-activated DNase, were also
cleaved during apoptosis in at least one replicate (Figure S4, panel
E). Thus, it is tempting to speculate that cleavage of proapoptotic
Figure 3. Apoptoseq Validation. A. Quantitative PCR validations
were performed using primers against apoptotic peaks, with normal-
ization against a pair of negative control primers that did not map to
apoptotic peaks. In addition, the 180 bp apoptotic DNA was normalized
against uncut genomic DNA. A second pair of negative control primers
‘‘NegCont’’ was used to set the threshold for calling sites that passed.
From this analysis, all the sites passed. The columns represent the
average of three replicates. Error bars indicate standard errors. B.
Screenshot showing the apoptotic peak at a region that was validated,
HECW2.
doi:10.1371/journal.pone.0026054.g003
Figure 4. Apoptotic Breakpoints Associated with Genes. A.
Diagram of the distinct categories of locations. B. Graph of locations of
apoptotic DNA breakpoint peaks. C. Screenshot of apoptotic breakpoint
peaks with regards to UCSC Gene exon density in chromosome 14.
doi:10.1371/journal.pone.0026054.g004
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cells to incorporate the cleaved DNA fragments into their genome
and through the ensuing growth advantages possibly conferred by
the ensuing gene translocations to survive and proliferate in the
continued presence of the proapoptotic stimuli.
Further Characterization of Apoptotic DNA Breakpoints
To functionally annotate the DNA breakpoints, we compared a
DNase I Hypersensitivity map as an indicator of regions of open
chromatin [48], a H3K4me3 ChIP-Seq map as this histone
modification is associated with active gene transcription [49], and
a CTCF (CCCTC-binding factor) ChIP-Seq map as CTCF is a
zinc finger protein which organizes chromatin, acts as an insulator
[50], and is also associated with DNase I hypersensitive sites and
Sono-Seq open chromatin regions sites [51,52]. These maps were
produced in HL-60 cells by the ENCODE consortium (Stama-
toyannopoulos and colleagues, University of Washington) [53].
In contrast to randomly selected sites in the human genome
which showed only 0.7% (1823 of 248999) associated with DNase
I hypersensitivity, approximately 15% (1090 of 7413) of DNA
breakpoints in the AHH001 fragment library and 8% of apoptotic
breakpoints in AHH002 (20049 of 255488) were associated with
DNase I hypersensitive sites. These associations were significant
(Binomial p-value=0 for both AHH001 and AHH002) (Figure 5,
panel A), suggesting that genomic sequences located in regions of
open chromatin and actively transcribed were particularly
susceptible to cleavage during apoptosis.
In addition, 4% (303 of 7413) of DNA breakpoints in AHH001
and 3% in AHH002 (6922 of 255488) were marked by H3K4me3.
By contrast, only 0.2% (598 of 248999) of random genomic
sequences were associated with H3K4me3 marks. The association
between apoptotic breakpoints and H3K4me3 marks was
significant (Binomial p-value=0 for both AHH001 and
AHH002) (Figure 5, panel A), further emphasizing that actively
transcribed genes located in regions of open chromatin were
particularly prone to apoptotic cleavage.
Finally, 5% (367 of 7413) of DNA breakpoints in AHH001 and
3% in AHH002 (6926 of 255488) were identified as CTCF sites.
By contrast, only 0.2% (573 of 248999) of random sites showed
CTCF marks. This association (Binomial p-value=0 for both
AHH001 and AHH002) (Figure 5, panel A); pointed to the
association of apoptotic DNA breakpoints with insulator regions.
To complete these analyses, we also examined the regions of the
DNA breakpoints for the presence of motifs representing potential
transcription factor binding sites using the Centdist software [54].
These analyses indicated that the binding sites for selected
transcription factors, such as HNF4, LRF, and RREB, were
significantly enriched in both fragment libraries (Figure 5, panel
B). HNF4 (hepatocyte nuclear factor 4) is part of the hepatocyte
nuclear factor/Met axis that is aberrantly expressed in cancers
[55]. Moreover, expression profiling has revealed that HNF4
target genes were often associated with apoptosis [56]. LRF, also
called Pokemon, is another transcriptional repressor associated
with cancer [57]. In contrast to LRF, which is a transcriptional
repressor, the transcription factor, RREB (Ras-responsive element
binding protein), which activates p53 to control apoptosis [58],
was also identified in these analyses. Interestingly, two RAS genes
(H-RAS and K-RAS) also displayed significant apoptotic break-
points in at least one biological replicate (Figure S4, panel F),
potentially suggesting that cleavage of some cancer-associated
genes may also occur during apoptosis. Interestingly, many of
these transcription factors bound poly-C motifs, which was
consistent the high GC content of the apoptotic DNA breakpoint
peaks highlighted in this study. Specifically, we found transcription
factors, such as AP-2rep (KLF12), from the cancer-associated
Kru ¨ppel-Like Factor (KLF) family, which bind a CACCC motif
(Figure 5, panel C) [59].
In conclusion, many human cancers have been separately linked
to gene translocations and altered control of apoptosis. Studies of
apoptosis using microarrays, proteomics, and other technologies
are limited to the analysis of transcribed genes and/or their
protein products. While valuable in providing insights into the
apoptotic process, they have not revealed the role of DNA strand
breaks that occur during apoptosis.
In this work, we developed a new method, Apoptoseq, to
investigate the specific regions of the genome cleaved during
apoptosis. We successfully applied Apoptoseq to study end-
repaired fragments of apoptotic DNA, suggesting that even clinical
cancer samples which show high amounts of fragmented apoptotic
DNA may still be amenable to next-generation sequencing.
Our results illustrated a pattern of non-random DNA break-
points in apoptotic cells whereby specific DNA regions rather than
sequences experiences preferential cleavage by CAD, which
activated during apoptosis. The selectivity of this DNA cleavage
mechanism may spare certain DNA elements and genes, which
can be engulfed by other cells to promote horizontal gene transfer,
and the incorporation and activation of these genes may
contribute to cancer progression. The cleavage of some genes
such as CASP3 may preclude the activity of these genes following
Figure 5. Characterisation of Apoptotic DNA Breakpoints. A.
Association of apoptotic breakpoints with H3K4me3 marks, DNase I
hypersensitivity marks, and CTCF marks. B. Transcription factor motifs
found in apoptotic breakpoints from both AHH001 and AHH002
biological replicates. C. Examples of transcription factor motifs found in
only one apoptoseq replicate, AHH002.
doi:10.1371/journal.pone.0026054.g005
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apoptosis. DNA repair of the apoptotic DNA fragments may
generate gene translocations, which in turn may allow cells that to
gain some growth advantage and progress into tumors. As many
translocations arise in non-random ‘‘hotspots’’ [60], and since
‘‘chromothripsis’’ (a catastrophic genome shattering event similar
to that of the induction of apoptotic DNA cleavage [27]) has been
described to occur in cancer cells, we speculate a potential
mechanistic link between DNA cleavage during apoptosis and
gene translocations (Figure S7).
In vitro studies have failed to identify a unique DNA sequence
motif recognized by CAD [61]. In this regard, our findings suggest
that gene-rich regions in open regions of chromatin bound by
specific transcription factors and actively transcribed may be
particularly susceptible to cleavage during apoptosis suggesting a
more complex mode of recognition of the genome by CAD. As
many histones may be dephosphorylated upon apoptosis, this and
other epigenetic mechanisms may also induce chromatin confor-
mations that facilitate the access to CAD [62]. Currently, the
impact of distinct apoptotic signaling pathways or mechanisms in
the pattern of DNA cleavage remains unknown. Apoptoseq
analyses of normal and cancer cells exposed to different cytotoxic
agents could provide new insights into the diversity of DNA
breakpoints elicited by anticancer drugs and thereby point their
usefulness as genetic fingerprints or biomarkers of drug-induced
cell death. In particular, future studies using non-genotoxic
inducers of apoptosis, such as corticosteroids, may be very useful
in potentially differentiating DNA breaks induced by a genotoxic
agent, as used in this study. Apoptotic biomarkers might be
obtained that highlight when the activation of apoptosis may
facilitate gene translocations to promote drug resistance and be a
prelude to the formation of more aggressive tumors.
Materials and Methods
Analysis of Apoptosis
Apoptosis was confirmed by Western Blot analyses (three
replicates) as previously described [63] using cell lysates prepared
in ice-cold RIPA buffer supplemented with Protease Inhibitor
Complete cocktail (Roche). Antibodies that recognized cleaved
PARP (Abcam), as well as anti- tubulin antibodies (Sigma) were
used for immunoblotting and detected using with horseradish
peroxidase-linked goat anti-mouse IgG and goat anti-rabbit IgG
from Santa Cruz Biotechnology.
Isolation of Apoptotic DNA
Apoptotic DNA ladders generated by treating HL-60 cells with
0.5 mg/ml Actinomycin D (Sigma) for 19 h were prepared using
the Merck Suicide-Track kit. Selected DNA fragments were
subjected to RNase ONE (Promega) digestion followed by
Proteinase K treatment (Sigma). The 180 bp or 360 bp bands
were excised following electrophoresis on 1.9% agarose gels and
further purified using Qiaquick gel extraction kit (Qiagen). The
purified DNA was quantitated by Nanodrop and three replicates
prepared for analysis by quantitative PCR.
Preparation of Genomic DNA
As a control for qPCR analyses and normalizing for inherent
genomic aberrations, HL-60 cells (from Marc Fivaz, Duke-NUS
Graduate Medical School) were grown in RPMI-1640 media
supplemented with 10% heat-inactivated Fetal Bovine Serum at
37uC in a humidified 5% CO2 incubator. RNA-free genomic
DNA was harvested from the cells using a Sigma genomic DNA
extraction kit according to the manufacturer’s protocols.
Generation of Apoptoseq Libraries
Apoptotic DNA was obtained from lyophilized 1610
6 HL-60
human leukemia cells treated with 0.5 mg/ml Actinomycin D for
19 h provided with the Merck Suicide-Track kit (positive control
part no: D00073752). An additional biological replicate was also
obtained from Merck (positive control part no: D00063279). The
180 base-pair band was excised from 1.9% agarose gels and
purified with a Qiaquick gel extraction kit (Qiagen). The smallest
DNA fragments were used for Next-Gen sequencing as this
represented the most extensively cleaved apoptotic DNA frag-
ments that would likely encompass, both early and late DNA
breaks. An added benefit is that 180 bp DNA fragments are well
suited to next-generation sequencing although other bands could
also be examined in future experiments. Representative agarose
gel images are shown in Figure S1. Next, we subjected the DNA
preparation to RNase ONE (Promega) digestion to remove any
contaminating RNA and the resulting DNA was purified using the
MinElute kit (Qiagen) to remove the RNase.
The concentration of the purified 180 bp DNA was quantitated
using Nanodrop, visualized by Agilent Bioanalyzer to ensure that
the pure DNA was submitted to 1
st BASE Pte Ltd for next-
generation sequencing ABI SOLiD library preparation and 50-
base single-end sequencing according to manufacturer’s protocols
for the ABI SOLiD 3 system. The equivalent of one octet (one-
eighth of a SOLiD 3 sequencing plate, onto which DNA is placed
for sequencing) was used per library for one replicate of
Actinomycin D-treated HL-60 cells (replicate no: D00073752).
This library was labeled AHH001 (Table 1).
To investigate the possibility of large variations in library
construction that could subsequently confound the sequencing, we
prepared two technical replicate libraries. The two technical
replicate libraries were prepared from replicate no: D00063279
and each sequenced with the equivalent of one octet. This library
was labeled AHH002, and the two technical replicate libraries
were identified as AHH002A and AHH002B (Table 1).
The term ‘‘equivalent’’ is used to only indicate that barcoding of
samples and pooled sequencing was performed on samples
followed by deconvoluting the barcodes. Barcoding and pooled
sequencing was performed in order to reduce sequencing costs, by
allowing for different samples to be sequenced together in the
same DNA plate.
Identification of DNA Breakpoints by Apoptoseq
First, we aligned raw DNA sequences to the human genome to
identify the origins of the DNA. Specifically, ABI SOLiD data was
mapped to the human genome assembly hg19, using Batman
(http://code.google.com/p/batman-aligner/, Tennakoon et al,
manuscript in preparation). Batman is a Burrows-Wheeler-
Transform-based (BWT) method that quickly maps short
sequences to a reference genome. We sequenced the ends of the
180 bp DNA fragments, in numerous repeat experiments. We
predicted that randomly cleaved DNA would be less likely to be
sequenced in many repeat experiments and thus, would distribute
in a scattered or random manner across the genome. In contrast,
the apoptotic cleaved DNA would be more clustered. Specifically,
we performed ‘‘peak-calling’’ (‘‘peaks’’ indicate clusters of regions
which were sequenced frequently) on the uniquely mapped reads
with identical duplicates (which are likely the result of clonal PCR
amplifications) merged using the MACS package frequently used
for ChIP-Seq applications [38]. Visual inspection of the data and
preparation of screenshots was carried out through uploading
tracks of the results to an in-house BASIC browser (Mulawadi
et al., manuscript in preparation). Peaks within highly repetitive
satellite regions as indicated by RepeatMasker (Smit, AFA,
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Program; http://www.repeatmasker.org) were attributed to noise
due to non-specific mapping and excluded from further analyses,
as were peaks within ChrY, noise arising from HL-60, a female cell
line. Peaks present in known copy number changes in HL-60 cells
[64] were not excluded from these analyses, but were flagged in
Table S2.
Analyses of Apoptotic DNA Breakpoints
To calculate overlaps between the two libraries, first, we
standardized Apoptoseq peaks through calculating the centre of
each peak +/2200 bp. Next, we identified all overlaps, requiring
at least 1 bp to call an overlap. We then listed this region as an
‘‘overlapping’’ apoptotic breakpoint in library A. To calculate the
percentage of overlaps for library A, we took the number of
overlapping apoptotic breakpoints divided by the total number of
apoptotic breakpoints for the library A.
Gene analysis was undertaken using UCSC gene transcripts
[65]. The center of each peak was identified and checked first for
overlaps of the peak with gene promoters (+/22.5 kb around the
transcription start sites). If a positive overlap was observed, these
peaks were defined as a ‘‘promoter peaks’’. Next, we checked the
remaining peaks for overlaps with exons and where overlapping,
these peaks were defined as ‘‘exon peaks’’. All remaining peaks
from above analyses for overlaps with genes were defined as
‘‘intron peaks’’. In addition, we checked these peaks for overlaps
with regions 2.5 kb downstream of the transcription end sites and
where overlapping, defined these as ‘‘39 region peaks’’. Peaks
overlapping with regions 2.5 kb–20 kb upstream of gene tran-
scription start sites were defined as ‘‘distal to the promoter peaks’’
or ‘‘distal promoter’’. Peaks, classified as ‘‘intergenic’’, showed no
association with any genes.
We analyzed all apoptotic DNA breakpoint peaks for
percentage GC content. H3K4me ChIP-Seq, CTCF ChIP-Seq
and DNaseDNase I hypersensitivity maps produced from HL-60
cells by Stamatoyannopoulos and colleagues at University of
Washington as part of the ENCODE consortium [53] were
downloaded from the UCSC Genome Browser, and converted
from hg18 to hg19 genome assembly using the UCSC LiftOver
tool [66,67]. These peaks were standardized to a range of 149 bp.
If the center of an Apoptoseq peaks fell within the H3K4me3,
CTCF, and DNase I hypersensitivity peaks, this identified the
overlapping peaks.
To analyze the associations between apoptotic breakpoint-
associated genes, cancer-associated genes, and translocation-
associated genes, we utilized the list of UCSC genes, where genes
encoding distinct isoforms of the same gene product were counted
as one gene. Through this, we obtained a list of 29,209 genes
within the entire human genome, which were analyzed for
overlaps with the cancer-associated and translocation-associated
genes curated by Wellcome Trust Sanger Institute [47].
For the random analyses, 250,000 peaks were simulated from
the human genome. After removal of peaks within chromosome Y
and satellite regions, 248,999 peaks were examined for their
distributions with respect to genes, H3K4me3 data, CTCF data
and DNase I hypersensitivity.
Motif analyses
In addition, we performed transcription factor binding site motif
analyses on the full dataset of peaks using Centdist [54].
Statistical analyses
We used Pearson’s chi-square statistical tests to calculate the
significance of the association between apoptotic DNA breakpoints
and genes, including the translocated genes. We used the binomial
distribution to calculate the significance of the association between
apoptotic DNA breakpoints and H3K4me3 ChIP-Seq, CTCF
ChIP-Seq or DNaseDNase I hypersensitivity peaks.
Quantitative PCR
Quantitative PCR was performed on 180 bp or 360 bp
apoptotic DNA excised from agarose gels, or the entire apoptotic
DNA ladder (all apoptotic DNA purified from the Merck Suicide
track kit, without further purification by agarose gel electropho-
resis) from Actinomycin D-treated HL-60 cells with apoptotic site-
specific primers (Table S3), with double normalization against
uncut genomic DNA (prepared by a Sigma genomic DNA kit
according to manufacturer’s protocols, including a RNase A-
treatment) at the same site and against a negative control primer
(which hybridized to a region without high apoptosis cleavage as
previously used [68]). The delta-delta-Ct Fold change calculation
method commonly used in reverse transcriptase quantitative PCR
(RT-qPCR) was used for double normalization. 3 biological
replicates from the Merck Suicide-Track kit were analyzed (from
replicate nos. D00073752, D00063279, D1000431).
The 180 bp or 360 bp purified DNA from apoptotic ladders, or
apoptotic ladders, or uncut genomic DNA (1 ng quantitated by
Nanodrop or Agilent Bioanalyzer), was used in 10 ml of SsoFast
Evagreen reaction mix (Bio-rad) and analyzed on a Biorad iQ5
real-time quantitative PCR machine according to standard
SsoFast quantitative PCR programs. At least 3 technical replicates
were analyzed per reaction, and the standard error of the technical
replicates was established at less than 0.5. Primers were designed
by Primer3 [69] or Roche Lightcycler’s free quantitative PCR
design program (http://www.roche-applied-science.com/lightcyc
ler-online/) at non-repetitive regions identified by Repeatmasker
(Smit, AFA, Hubley, R & Green, P. RepeatMasker Open-
3.0.1996–2010 Program; http://www.repeatmasker.org) were
verified to show sharp melting curves with efficiencies between
90% and 110%, and are listed in Table S2.
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